Adebrelimab plus chemo for advanced bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests adding the immunotherapy adebrelimab to standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for advanced biliary tract cancer that can't be removed by surgery. The goal is to see if this combination helps shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have advanced bile duct or gallbladder cancer that has not been treated before, or came back after surgery.
- You are able to care for yourself (ECOG score 0 or 1) and expected to live at least 3 months.
- Your blood counts, liver, and kidney function must be within certain safe limits.
- You cannot have a history of autoimmune disease or use long-term steroids.
- You must agree to use effective birth control during and for 120 days after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, an immunotherapy drug called adebrelimab, and a supportive medication to shrink bile duct or gallbladder tumors before surgery. The goal is to make the tumor easier to remove and improve outcomes.
This trial is for people with bile duct cancer who have had surgery to remove all visible cancer but are at high risk of it coming back. It tests whether adding two medications — adebrelimab (an immunotherapy) and capecitabine (a chemotherapy pill) — after surgery can help prevent the cancer from returning.
This trial tests a combination of three drugs for bile duct cancer that cannot be removed by surgery: sintilimab (an immunotherapy that helps your immune system fight cancer), bevacizumab (a drug that blocks blood vessel growth to tumors), and a standard chemotherapy called AG (gemcitabine and capecitabine). The goal is to see if this combination can help shrink or control the cancer as a first treatment option.
This trial is testing whether a new drug (SHR-8068) combined with adebrelimab and chemotherapy works better than the current standard treatment for people with advanced bile duct cancer who have not been treated yet.
This trial tests a new combination of a drug that helps your immune system fight cancer, called sintilimab, along with chemotherapy. It is for people who have bile duct cancer or gallbladder cancer that has spread to other parts of the body and have not had treatment for this stage yet. The goal is to see if this combination helps shrink tumors or stops them from growing.
This study tests a combination of three medicines (adebrelimab, apatinib, and standard chemotherapy) for people with newly diagnosed bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if the combination can shrink the tumor and make it possible to remove later.
Hear when a new Biliary Tract Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.